BRCA1 and BRCA2 proteins are key components of the homologous recombination repair pathway for repairing double-stranded DNA breaks.  Mutations in BRCA genes can significantly increase the risk of certain cancers such as breast, ovarian, pancreatic, and prostate cancer. To mimic the effects of BRCA2 deficiency in humans, WuXi Biology has constructed a BRCA2 deficient mouse …Read More >

Cyclin-dependent kinases (CDKs) and their cyclin regulatory subunits form complexes that are essential for driving abnormal growth processes in cancer cells, making these proteins important targets for cancer treatment. To support the discovery of novel CDK inhibitors, the WuXi AppTec Discovery Biology Structural Biology platform provides a wide range of biophysical, X-ray crystallography, and cryo-EM …Read More >

Signal transducer and activator of transcription (STAT) proteins are key mediators of cellular immunity, proliferation, apoptosis, and differentiation. STATs are known to play a key role in the pathogenesis of many different diseases (including cancer) and the development of drugs directly or indirectly targeting STAT signaling is a major focus for researchers. The WuXi AppTec …Read More >

Frequently observed in NSCLC patients, the 4 amino acid YVMA insertion is the most common type of HER2 exon 20 insertion mutation. A secondary mutation, C805S, often develops as a mechanism of resistance to HER2 tyrosine kinase inhibitors (TKIs) such as poziotinib, where the C805 residue is crucial for drug binding.  The presence of a …Read More >

Homozygous deletion of methylthioadenosine phosphorylase (MTAP) in cancers such as glioblastoma represents a potentially targetable vulnerability. MTAP deletions occur in approximately 10 – 15% of all human cancers. When the MTAP gene is deleted, methylthioadenosine (MTA) accumulates and selectively inhibits PRMT5. This creates a synthetic lethal dependence on PRMT5 in MTAP-deleted tumors. As a potential …Read More >

In recent years, bispecific antibodies (BsAbs) have emerged as a novel strategy in tumor immunotherapy. BsAbs combine two distinct antigen targets within a single antibody molecule, potentially enhancing clinical efficacy and safety. As a result of this dual targeting approach, the clinical therapeutic effects of BsAbs are considered superior to those of monoclonal antibodies. WuXi …Read More >

Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in Western populations. Targeted therapies, including the use of BTK inhibitors, have significantly improved the care of patients with CLL. However, over time, many patients develop resistance to these drugs. Acquired resistance to the BTK inhibitor ibrutinib is mediated by the C481S mutation, …Read More >

Viruses have well-established causal roles in numerous human cancers. Approximately 10% of cancers globally are attributed to viral infections, primarily from viruses like HPV, EBV, HBV, and HCV. The innate and adaptive immune systems play important roles in oncogenic viral infection and subsequent cancer development. As viral cancers have viral-specific targets and biomarkers, there is …Read More >

Fibroblast growth factor receptor (FGFR) signaling pathways represent promising targets for therapeutics owing to their role in development, tissue, and whole-body homeostasis, as well as in many cancers. To support drug discovery programs, we have established off-the-shelf crystallization systems to enable the determination of high-resolution X-ray crystal structures with a short turnaround time. Together with …Read More >